| An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2) |
Ongoing |
A4250 |
3 |
A4250-008 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A phase II, multicenter, open label study of treatment escalation to ACVD (Adriamycin, Cyclophosphamide, Vinblastine and Dacarbazine) and Brentuximab-Vedotin in advanced-stage Hodgkin Lymphoma patients with a positive interim PET scan after 2 ABVD cycles (OPTIMIST study) |
Ongoing |
• DOXORUBICIN HYDROCHLORIDE• CYCLOPHOSPHAMIDE• VINBLASTINE SULPHATE • DACARBAZINE• BRENTUXIMAB VEDOTIN |
2 |
RC16/150 |
King Abdulaziz Medical City NG (Riyadh) |
| "ALL SCTped 2012 FORUMAllogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia" |
Completed |
• BUSULFAN• FLUDARABINE PHOSPHATE• ETOPOSIDE |
3 |
CT17/016/R |
King Abdulaziz Medical City NG (Riyadh) |
| Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemophilia B (FIX:C<2%) (BeneGene-2) |
Ongoing |
PF-06838435 |
3 |
C0371002 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Single arm Phase I/II study of the safety, tolerability and efficacy of the Tocilizumab followed by cisplatin/docetaxel in patients with triple negative locally advanced breast cancer |
Ongoing |
• TOCILIZUMAB (ACTEMRA)• DOCETAXEL (TAXOTERE)• CISPLATIN |
2a |
2181156 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Re-challenge therapy with chemotherapy and panitumumab in metastatic colorectal cancer patients treated with an anti-EGFR therapy in 1st line treatment: a phase II multicentre study. |
Ongoing |
• PANITUMUMAB• OXALIPLATIN• irinotecan• FLOUROURACIL |
2 |
19-504 |
King Abdullah Medical City (Makkah) |
| "A multicenter, multinational, prospective, interventional,single-arm, Phase IV study evaluating the clinicalefficacy and safety of 26 weeks of treatment with insulin glargine 300 U/mL (Gla-300) in patients with Type 2 diabetes mellitus uncontrolled on basal insulin" |
Ongoing |
TOUJEO |
4 |
LPS15396 |
Sultan bin Abdulaziz Humanitarian city (Riyadh) |
| An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension |
Ongoing |
Interferon beta-1a |
3 |
105MS306 |
King Faisal Specialist Hospital and Research Center (Jeddah), King Khalid University Hospital (Riyadh) |
| A prospective Randomized study of General Anesthesia versus Anesthetist Administered sedation for ERCP |
Ongoing |
FENTANYL/ CISATRACURIUM/ SEVOFLURANE |
4 |
18-492 |
King Abdullah Medical City (Makkah) |
| "A multi-centre prospective non-interventional studyinvestigating the clinical effectiveness of Ryzodeg® (InsulinDegludec/Insulin Aspart) in patients with type 2 diabetesmellitus in a real-world setting" |
Ongoing |
Ryzodeg Flex Touch |
4 |
NN54014525 |
King Abdulaziz University Hospital (Jeddah), Ghassan Najeeb Pharaon hospital (Jeddah), Saudi German Hospital (Jeddah), Umm Al-Qura University (Makkah), Dallah Hospital (Riyadh), Riyadh Care Hospital (Riyadh), Specialized Medical Center (Riyadh), King Abdulaziz Medical City NG (Riyadh) |
